急性髓系白血病靶向治疗药物的研究进展  

Research progress of targeted therapeutic drugs for acute myeloid leu-kemia

作　　者：王圣勇 候雪婷 顾培馨 鲍计章[1] WANG Shengyong;HOU Xueting;GU Peixin;BAO Jizhang(Department of Hematological,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai200071,China)

机构地区：[1]上海中医药大学附属市中医医院血液病科,上海200071

出　　处：《中国医药导报》2024年第9期67-70,共4页China Medical Herald

基　　金：上海市“科技创新行动计划”医学创新研究专项项目(22Y11921100)。

摘　　要：急性髓系白血病(AML)是最具侵袭性的成人白血病,大量的临床前和临床研究推动了美国食品药品监督管理局逐步批准了数种适用于AML的靶向药物。然而,大多数患者的预后仍然不佳,而且常因耐药突变克隆导致疾病复发。因此,临床上仍需要进一步研究新的靶向药物,或提出创新性的、更为合理的用药方案。本文综述了包括B淋巴细胞瘤-2基因抑制剂、异柠檬酸脱氢酶抑制剂、FMS样酪氨酸激酶3抑制剂和TP53抑制剂药物的临床研究进展,并简述这些药物在AML治疗中的地位及作用,为未来治疗方案制订的精准化、个体化提供思路。Acute myeloid leukemia(AML)is the most invasive adult leukemia,and a large number of preclinical and clinical studies have pushed the Food and Drug Administration to gradually approve several targeted drugs suitable for AML.However,the prognosis remains poor in most patients and disease often recurs due to drug resistant mutant cloning.Therefore,it is still necessary to explore new targeted drugs or propose innovative and more reasonable drug use schemes in clinic.This article reviews the progress of clinical research on B-cell lymphoma-2 inhibitors,isocitrate dehydrogenase inhibitors,FMS-like tyrosine kinase inhibitors,and TP53 inhibitors,and briefly describes the role and role of these drugs in the treatment of AML in order to provide ideas for the precision and individualization of future treatment plans.

关 键 词：急性髓系白血病 靶向药物 B淋巴细胞瘤-2 异柠檬酸脱氢酶 FMS样酪氨酸激酶3 TP53 

分 类 号：R733.71[医药卫生—肿瘤]